N4 Pharma PLC (N4P)
Delisted
LSE LSE Primary 
XSTU £
£
2.17M Market Cap
- P/E Ratio
72% Div Yield
- Volume
- Eps
£
Previous Close Day Range
0 0
Year Range
0 0
Want to track N4P and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.
N4P Chart
N4 Pharma PLC (N4P) FAQ
What does "Delisted" mean?
N4 Pharma PLC has been removed from the exchange and is no longer publicly traded.
What was the last recorded dividend?
No dividend payments were recorded prior to delisting.
How long did the company pay dividends?
The company did not have a dividend payment history.
Were there any stock splits?
The last recorded stock split occurred on May 03, 2017 with a ratio of 200:800.
What was the last known trading price?
Final trading price data is not available.
N4 Pharma PLC Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dr. David Horn Solomon M.D. CEO | LSE Exchange | G6362P106 CUSIP |
| United Kingdom Country | 4 Employees | - Last Dividend | 3 May 2017 Last Split | - IPO Date |
Overview
N4 Pharma Plc is a distinguished specialist pharmaceutical company operating out of London, United Kingdom. Since its incorporation in 1979, the company has been at the forefront of developing innovative silica nanoparticle delivery systems. These advanced systems are designed to serve the pharmaceutical and biotechnology sectors within the UK, offering new possibilities in the delivery of therapeutics. N4 Pharma Plc is dedicated to revolutionizing the healthcare industry by providing cutting-edge solutions that enhance the efficacy and delivery of vaccines and cancer treatments.
Products and Services
- Nuvec - A groundbreaking non-viral adjuvant delivery system primarily aimed at enhancing the delivery of vaccines and cancer treatments. Nuvec is an innovative solution developed by N4 Pharma Plc to address the limitations of current delivery systems in the biopharmaceutical industry. By employing silica nanoparticles, Nuvec significantly improves the stability and efficiency of therapeutic delivery, ultimately leading to more effective treatment outcomes. It stands at the forefront of N4 Pharma's efforts to contribute to the advancement of medical science and patient care.
Contact Information
Address: 2 Portman Street
Phone: 44 20 4610 0714
Website: https://www.thaliatx.com
